•  
  •  
  •  
  •  

2025-10-06 15:38:24

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Trishakti Industries Ltd successfully completes capex worth Rs. 74 crores
  • Tata Communications Launches Voice AI Platform to Transform BFSI Customer Journeys with Speed, Scale and Integrated Intelligence
  • Innovators Facade Systems Ltd receives LoA for order worth Rs. 87 crores
  • Mahanagar Gas Limited Puts Customers First with Salesforce Adoption, a First in India's CGD Sector
  • Alan Scott Enterprises Raises ₹12.50 Crore via Preferential Issue to Fuel Next Phase of Growth

Keywords Selected:  Wockhardt

Stock Report

  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • Leading U.K. Medical Journal publishes a Complex Case of Severe Pandrug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich®
  • Wockhardt initiates strategic realignment of US Operations to focus on Innovative Portfolio
  • Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich™
  • Zaynich™ enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme drug resistant Gram negative pathogens
  • Wockhardt files fast-acting Insulin Aspart injection with DCGI
  • Wockhardt's yet another novel antibiotic Miqnaf™ receives favourable recommendation from Subject Expert Committee of CDSCO for the Treatment of CABP
  • Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai
  • Wockhardt's Investigational Drug, Zaynich™ cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use
  • Wockhardt wins prestigious Innovator Award from Government of India
  • Globally renowned US body CLSI awards high susceptibility breakpoints to Zaynich
  • Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
  • Wockhardt Ltd reports consolidated loss of Rs. 77 crores in Q2 FY2024
  • Wockhardt Ltd Q1FY24 consolidated loss at Rs. 134 crores
  • Wockhardt Ltd Q4 FY2023 consolidated loss at Rs. 208 crores
  • Wockhardt Ltd Q3 FY2023 consolidated loss at Rs. 96 crores
  • Ind-Ra revises ratings of Wockhardt Ltd
  • Wockhardt promoters sell stake, reinvest proceeds in the company
  • Wockhardt Ltd consolidated Q2FY23 loss widens to Rs. 189 crore
  • Wockhardt Limited updates on ratings
  • Wockhardt Ltd closes Illinois manufacturing facility
  • Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
  • Wockhardt Ltd allots 3,32,44,650 Equity Shares

Latest Post

  • Trishakti Industries Ltd successfully completes capex worth Rs. 74 crores
  • Tata Communications Launches Voice AI Platform to Transform BFSI Customer Journeys with Speed, Scale and Integrated Intelligence
  • Innovators Facade Systems Ltd receives LoA for order worth Rs. 87 crores
  • Mahanagar Gas Limited Puts Customers First with Salesforce Adoption, a First in India's CGD Sector
  • Alan Scott Enterprises Raises ₹12.50 Crore via Preferential Issue to Fuel Next Phase of Growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024